Stefan R. Bornstein
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Background Double filtration plasmapheresis (DFPP) is a membrane‐based apheresis technique that separates plasma components using two sequential filters; it is commonly used to remove high‐molecular‐weight substances across various indications. While various metrics such as “plasma removal efficiency” are well established in therapeutic plasma exchange, “plasma separation efficiency” (PSE) remains unreported in DFPP. This study aims to evaluate PSE across DFPP sessions performed with plasma filters of different pore sizes. Materials and Methods A retrospective study of DFPP procedures performed in patients with hyperlipidemia at a single center between April and July 2025 was conducted. Patient demographics, laboratory values, and procedural parameters were collected. PSE was calculated with and without hematocrit (HCT) adjustment (PSE 1 and PSE 2 ). Associations with procedural variables were assessed using paired tests and multivariate linear regression. Results A total of 42 DFPPs were performed in 19 patients using the Inuspheresis system, alternating two plasma fractionators (DFPP‐1 and DFPP‐2 with large and small pore size, respectively). PSE 2 and PSE 1 declined significantly from DFPP‐1 to DFPP‐2 ( p = 0.0002 and p = 0.0014, respectively), with Cohen's d indicating large and moderate‐to‐large effect sizes. DFPP also resulted in significant reductions in total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, lipoprotein(a), and C‐reactive protein. Multivariate models showed that the plasma separation rate and HCT shifts were significantly associated with PSE 2 and PSE 1 during DFPP‐2 but not during DFPP‐1. Conclusions PSE is a reproducible parameter influenced by membrane pore size and procedural factors. Incorporating PSE monitoring, particularly with HCT adjustment, may support optimization of individualized DFPP protocols in routine apheresis practice.
Year:
2026
Double filtration plasmapheresis (DFPP) is a promising method for removing environmental toxins, but comparative data on toxin‐specific removal patterns remain limited. This study investigates the removal effectiveness of various pollutants in patients with hyperlipoproteinemia(a) undergoing DFPP. We retrospectively analyzed procedures performed using the Inuspheresis System with two filters with differing pore sizes. We assessed the clearance of heavy metals, volatile organic compounds, and organic pollutants by calculating the “ redistribution ratio ” (RR) and the percentage of captured analyte (CA). Analytes with large volumes of distribution and low protein binding, such as toluene, methyl isobutyl ketone, and barium, showed high rebound (RR: 1.95, 1.31, and 1.97, respectively), suggesting redistribution from peripheral compartments. Moderate rebound was observed for partially protein‐bound toxins, including PCB 153 (0.76), PCB 138 (0.74), and hexachlorobenzene (0.66). Low or negative RRs were seen with arsenic (−0.49), mercury (−0.05), and cobalt (0.08), likely reflecting limited redistribution. High CA values were recorded for lipophilic, protein‐bound toxins such as PCBs and p,p′‐DDE. Herein, we demonstrate that DFPP is effective in removing environmental toxins from the human body. The pharmacokinetic properties of each compound are key determinants of DFPP effectiveness and may help guide the development of personalized detoxification strategies to optimize its clinical use.
Year:
2025
Phaeochromocytomas (PCCs) and paragangliomas (PGLs), are rare neuroendocrine tumours that arise in the neural crest (NC)-derived adrenal medulla and the paraganglia, respectively. Approximately 10%-15% of patients with PCCs and 35%-40% with PGLs go on to develop metastatic disease, leading to a reported median overall survival of 7 years. The development of prognostic markers and subsequent personal therapeutic strategies are hindered by a lack of understanding of tumourigenesis. In other organs, cells with stem-like properties are at the root of tumour initiation and maintenance, due to their ability to self- renew and give rise to differentiated cells. We have recently shown that, in the human adrenal, a subset of sustentacular cells, endowed with a support role, are in fact SOX2+ postnatal adrenomedullary stem cells, that are specified along the neural crest migratory route. In this study, we intended to determine if SOX2+ cells in PCCs and PGLs can behave as tumour-initiating stem cells. Using expression and transcriptomic studies, we demonstrate the presence of SOX2/ SOX2 -expressing cells across a broad range of PCCs and PGLs, irrespective of tumour aggressiveness, location, and causative mutation. In silico analyses reveal the co-expression of SOX2 and chromaffin cell markers in the tumour, and the active proliferation of these double-positive cells. Isolation of these cells in vitro in stem cell-promoting media, and their xenotransplantation on chicken chorioallantoic membranes, demonstrates that they have the potential to expand and metastasise in ovo , supporting their potential as tumour-initiating cells.
Year:
2025
Long-term complications, such as extensive fatigue and cognitive issues, are known from various infections, including SARS-CoV-2, influenza virus, or Borrelia burgdorferi . The pathology is mostly unknown and differs between patients. Unfortunately, there is currently no common and effective treatment. In this perspective, we imply that post-acute infectious syndromes are due to a variety of factors, including among others diminished tissue perfusion, tissue infiltration by viruses, inflammation, and oxidative stress, and that not one specific biomarker can be used to measure these syndromes. Thus, we suggest that a score based on a number of criteria/factors should be used to assess post-acute infectious syndromes. Consequently, probably not one single treatment can be used to treat this group of patients, and we suggest a multimodal treatment regimen comprising a combination of pharmacotherapy, such as metformin and naltrexone with anti-inflammatory effects, alongside physical therapies such as extracorporeal apheresis and transcutaneous neurotherapy. This combined approach aims to reduce biomarker levels and enhance cognitive functions. This implies that a reset of the systems can be achieved by a multimodal approach based on a score for post-acute infectious syndromes.
Year:
2024
Professor Stefan Bornstein currently serves as the Chair of Medicine at the University of Dresden, Germany and Transcampus Dean at King's College London, UK. His extensive experience in the United States and Europe has equipped him with unparalleled expertise, particularly in diabetes and endocrinology. Professor Bornstein has authored over 700 publications, garnering more than 100,000 citations with an impressive h-index above 120. His work is frequently featured in journals such as the New England Journal of Medicine, Nature , and Science . Professor Bornstein's contributions extend beyond academia into influential leadership roles, such as founding the first European Transcampus between King's College and the University of Dresden and initiating the German Australian Institute of Translational Medicine. His achievements have earned him numerous awards, including the Order of Merit of Germany (Bundesverdienstkreuz 1. Class), the highest state distinction in Germany, the Medal of Honour of the University of Dresden, and membership in both the European and German Academies of Sciences. In 2023 Professor Stefan Bornstein became a member of the Freedom of the City of London, in recogntion of both his individual contributions and the success of the TransCampus project. Honorary citizenship of London has existed since the 13 th century and originally enabled recipients, who were also required to join a Livery company, to carry out their trade in London. Whilst this practical element no longer applies, the City of London has maintained the Freedom as a living tradition. These accolades reflect his exceptional contributions to medical science and education. We are privileged to share Professor Bornstein's answers to the Genomic Press Interview with our readers.
Year:
2024
For the past 100 years, insulin supplementation has been the mainstay of treatment for type 1 diabetes (T1D), which is characterized by progressive autoimmune-mediated loss of insulin-producing β cells in the islets of Langerhans over the last decades, technological advances in glucose monitoring and therapeutics have greatly improved the care and management of these patients. However, morbidity, mortality, and quality of life remain challenges for patients with T1D. Islet transplantation has been successfully performed, but there are several limiting factors, such as the lack of cadaveric donors and the need for lifelong immunosuppressive therapy. Therefore, there is a great medical need for alternative therapeutic approaches. In the current review, the current knowledge on novel approaches for the treatment of T1D with a focus on the potential of using chimeric antigen receptor (CAR)-T cells and natural killer (NK) cells is summarized.
Year:
2024
Artificial intelligence (AI) has gained attention for various reasons in recent years, surrounded by speculation, concerns, and expectations. Despite being developed since 1960, its widespread application took several decades due to limited computing power. Today, engineers continually improve system capabilities, enabling AI to handle more complex tasks. Fields like diagnostics and biology benefit from AI’s expansion, as the data they deal with requires sophisticated analysis beyond human capacity. This review showcases AI’s integration in endocrinology, covering molecular to phenotypic patient data. These examples demonstrate AI’s potential and power in research and medicine.
Year:
2023
Collaborators (10)
Marily Theodoropoulou
Associate Professor
Ludwig-Maximilians-Universität München Medizinische Fakultät
Paul Chapple
Professor of Molecular Cell Biology
Queen Mary University of London
Charlotte Steenblock
University Hospital Carl Gustav Carus
Rebecca Oakey
Professor of Epigenetics
King’s College London
Nicole Toepfner
Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden
Cynthia L. Andoniadou
Professor of Stem Cell Biology
Queen Mary University of London
Nicole Bechmann
University Hospital Carl Gustav Carus
Milo Puhan
Director
University of Zurich
Christina Pamporaki
University Hospital Carl Gustav Carus Dresden
Louise Izatt
King’s College London
Make your next move.
Prepare your application
Review drafts before you send them.